Literature DB >> 33604602

Alpha 1-adrenoceptor signalling contributes to toxic effects of catecholamine on electrical properties in cardiomyocytes.

Mengying Huang1, Xuehui Fan1, Zhen Yang1, Lukas Cyganek2,3, Xin Li1, Goekhan Yuecel1,2, Huan Lan4, Yingrui Li1, Angela Wendel1, Siegfried Lang1,2, Karen Bieback5, Ibrahim El-Battrawy1,2, Xiaobo Zhou1,2,4, Ibrahim Akin1,2, Martin Borggrefe1,2.   

Abstract

AIMS: This study aimed to investigate possible roles and underlying mechanisms of alpha-adrenoceptor coupled signalling for the pathogenesis of Takotsubo syndrome (TTS). METHODS AND
RESULTS: Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were treated with a toxic concentration of epinephrine (Epi, 0.5 mM for 1 h) to mimic the setting of TTS. Patch-clamp technique, polymerase chain reaction (PCR) and Fluorescence-activated cell sorting (FACS) were employed for the study. High concentration Epi suppressed the depolarization velocity, prolonged duration of action potentials and induced arrhythmic events in hiPSC-CMs. The Epi effects were attenuated by an alpha-adrenoceptor blocker (phentolamine), suggesting involvement of alpha-adrenoceptor signalling in arrhythmogenesis related to QT interval prolongation in the setting of TTS. An alpha 1-adrenoceptor agonist (phenylephrine) but not an alpha 2-adrenoceptor agonist (clonidine) mimicked Epi effects. Epi enhanced ROS production, which could be attenuated by the alpha- adrenoceptor blocker. Treatment of cells with H2O2 (100 µM) mimicked the effects of Epi on action potentials and a reactive oxygen species (ROS)-blocker (N-acetyl-I-cysteine, 1 mM) prevented the Epi effects, indicating that the ROS signalling is involved in the alpha-adrenoceptor actions. Nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidases were involved in alpha 1-adrenoceptor signalling. A protein kinase C (PKC) blocker suppressed the effects of Epi, phenylephrine and ROS as well, implying that PKC participated in alpha 1-adrenoceptor signalling and acted as a downstream factor of ROS. The abnormal action potentials resulted from alpha 1-adrenoceptor activation-induced dysfunctions of ion channels including the voltage-dependent Na+ and L-type Ca2+ channels.
CONCLUSIONS: Alpha 1-adrenoceptor signalling plays important roles for arrhythmogenesis of TTS. Alpha-adrenoceptor blockers might be clinically helpful for treating arrhythmias in patients with TTS. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Acquired long QT syndrome; Adrenoceptor; Catecholamine excess; Human-induced pluripotent stem cell-derived cardiomyocytes; Takotsubo syndrome

Year:  2021        PMID: 33604602     DOI: 10.1093/europace/euab008

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  4 in total

1.  Dopamine D1/D5 Receptor Signaling Is Involved in Arrhythmogenesis in the Setting of Takotsubo Cardiomyopathy.

Authors:  Mengying Huang; Zhen Yang; Yingrui Li; Huan Lan; Lukas Cyganek; Goekhan Yuecel; Siegfried Lang; Karen Bieback; Ibrahim El-Battrawy; Xiaobo Zhou; Martin Borggrefe; Ibrahim Akin
Journal:  Front Cardiovasc Med       Date:  2022-02-04

Review 2.  Takotsubo Syndrome: Translational Implications and Pathomechanisms.

Authors:  Xuehui Fan; Guoqiang Yang; Jacqueline Kowitz; Ibrahim Akin; Xiaobo Zhou; Ibrahim El-Battrawy
Journal:  Int J Mol Sci       Date:  2022-02-10       Impact factor: 5.923

3.  Kidney Failure among Patients with Takotsubo Syndrome or Myocardial Infarction: A Retrospective Analysis.

Authors:  Verena Bill; Ibrahim El-Battrawy; Marvin Kummer; Andreas Mügge; Assem Aweimer; Michael Behnes; Ibrahim Akin
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-09

4.  Hyperthermia as a trigger for Takotsubo syndrome in a rat model.

Authors:  Matthew H Tranter; Bjorn Redfors; Peter T Wright; Liam S Couch; Alexander R Lyon; Elmir Omerovic; Sian E Harding
Journal:  Front Cardiovasc Med       Date:  2022-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.